The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    PS1 | Recruiting, Not yet recruiting Studies | Taiwan
Previous Study | Return to List | Next Study

Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05176210
Recruitment Status : Recruiting
First Posted : January 4, 2022
Last Update Posted : April 15, 2024
Sponsor:
Information provided by (Responsible Party):
Pharmasaga Co. Ltd.

Brief Summary:
This is a phase I, double-blind, placebo-controlled, randomized, single- and multiple-ascending dose study to evaluate new study intervention, PS1. PS1 is a potential blood glucose control medication, which is developed by Pharmasaga Co. Ltd. planned for treating type II diabetes mellitus (T2DM). This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), food effect and potential efficacy of PS1 in subjects.

Condition or disease Intervention/treatment Phase
Type II Diabetes Drug: PS1 Drug: Placebo Phase 1

Detailed Description:

This first-in-human Phase I study consists of a single ascending-dose (SAD) portion, a food effect (FE) portion, and a multiple ascending-dose (MAD) portion, aiming to evaluate the safety, tolerability, pharmacokinetics, food effect and potential efficacy of PS1 in healthy subjects.

A randomized, double-blinded, placebo-controlled study design will be applied for the SAD portion with three SAD dose cohorts-25 mg (Cohort 1), 50 mg (Cohort 2), and 75 mg (Cohort 3). An eligible subject in this portion will receive a single dose of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.

In FE portion, only one cohort (Cohort 4) is assigned. The FE cohort (Cohort 4) will use the same study design as the SAD cohorts. An eligible subject in this portion will receive a single dose of 50 mg PS1 or Placebo tablets in a fasted condition on Day 1 and be followed for 7 days.

Four cohorts are assigned in the MAD portion: 25 mg/day (Cohort 5 & 7) and 50 mg/day (Cohort 6 & 8) in healthy volunteers and participants respectively. Only the dose level of MAD lower than the maximum tolerated dose (MTD) of SAD portion can be activated (If 50 mg was determined as the MTD of SAD, only cohort 5 & 7 could be activated). An eligible subject will receive PS1 or Placebo tablets once daily in a fed condition for 14 days & 28 days in healthy volunteers and participants respectively and be followed for additional 7 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect and Potential Efficacy of PS1 in Subjects
Actual Study Start Date : December 22, 2023
Estimated Primary Completion Date : July 2025
Estimated Study Completion Date : July 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: SAD portion - Cohort 1 (25mg)
An eligible subject will receive a single dose of 25 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.
Drug: PS1
PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
Other Name: PS-001

Drug: Placebo
Placebo will be provided as a 120 mg tablet.

Experimental: SAD portion - Cohort 2 (50mg)
An eligible subject will receive a single dose of 50 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.
Drug: PS1
PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
Other Name: PS-001

Drug: Placebo
Placebo will be provided as a 120 mg tablet.

Experimental: SAD portion - Cohort 3 (75mg)
An eligible subject will receive a single dose of 75 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 7 days.
Drug: PS1
PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
Other Name: PS-001

Drug: Placebo
Placebo will be provided as a 120 mg tablet.

Experimental: FE portion - Cohort 4 (50mg)
An eligible subject will receive a single dose of 50 mg PS1 or Placebo tablets in a fasted condition on Day 1 and be followed for 7 days.
Drug: PS1
PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
Other Name: PS-001

Drug: Placebo
Placebo will be provided as a 120 mg tablet.

Experimental: MAD portion - Cohort 5 (25mg)
An eligible subject will receive 25 mg PS1 or Placebo tablets once daily in a fed condition for 14 days and be followed for additional 7 days.
Drug: PS1
PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
Other Name: PS-001

Drug: Placebo
Placebo will be provided as a 120 mg tablet.

Experimental: MAD portion - Cohort 6 (50mg)
An eligible subject will receive 50 mg PS1 or Placebo tablets once daily in a fed condition for 14 days and be followed for additional 7 days.
Drug: PS1
PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
Other Name: PS-001

Drug: Placebo
Placebo will be provided as a 120 mg tablet.

Experimental: MAD portion - Cohort 7 (25mg)
An eligible subject will receive 25 mg PS1 or Placebo tablets once daily in a fed condition for 28 days and be followed for additional 7 days.
Drug: PS1
PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
Other Name: PS-001

Drug: Placebo
Placebo will be provided as a 120 mg tablet.

Experimental: MAD portion - Cohort 8 (50mg)
An eligible subject will receive 50 mg PS1 or Placebo tablets once daily in a fed condition for 28 days and be followed for additional 7 days.
Drug: PS1
PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
Other Name: PS-001

Drug: Placebo
Placebo will be provided as a 120 mg tablet.




Primary Outcome Measures :
  1. Incidence of dose-limiting toxicity (DLT) during the DLT observation period [ Time Frame: Day 1~ Day 8 (SAD cohort); Day 1~ Day 35 (MAD cohort) ]
    DLT is defined as: (1) any adverse event (AE) ≥ Grade 3 (CTCAE v5.0) or (2) Grade 2 AE that does not resolve to grade 1 or less within 72 hours, that occurs in the DLT observation period and is causally related (possibly, probably, or definitely related) to the test article judged by the investigator.


Secondary Outcome Measures :
  1. Incidence of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: SAD, FE: up to 4 weeks; MAD: up to 8 weeks ]
    All adverse events (AEs) will be assessed for severity by the investigator based on NCI-CTCAE v5.0

  2. Number of participants with abnormalities in Vital signs [ Time Frame: SAD, FE: Baseline,1~2 weeks; MAD: Baseline,1~6 weeks ]
    Number of participants with abnormal systolic/diastolic blood pressure (in mmHg), respiratory rate, pulse rate (in beat per minute, bpm), and body temperature (in ℃)

  3. Number of participants with abnormalities in Laboratory examinations [ Time Frame: SAD, FE: Baseline,1~2 weeks; MAD: Baseline,1~6 weeks ]
    Number of participants with abnormal Hematology (hemoglobin, hematocrit, RBC, platelet, WBC, WBC differentials (neutrophils, eosinophils, basophils, lymphocytes, monocytes), MCV, MCH, MCHC), biochemistry (HbA1c, fasting plasma glucose, albumin, alkaline phosphatase, ALT, AST, BUN, creatinine, cholestero1, γ-GT, total protein, total bilirubin, direct bilirubin, triglyceride, amylase, lipase, calcium, sodium, potassium, chloride), and urinalysis (pH, protein, glucose, bilirubin, urobilinogen, ketone body, specific gravity, occult blood, RBC, WBC, creatinine, ratio of albumin/creatinine) results

  4. Acute kidney injury (AKI) marker [ Time Frame: SAD, FE: Baseline, 1~2 weeks; MAD: Baseline, 1~6 weeks ]
    Urine samples will be collected for analyzing acute kidney injury (AKI) markers

  5. Number of participants with abnormalities in 12-lead electrocardiogram (EKG) [ Time Frame: SAD, FE: Baseline, 1~2 weeks; MAD: Baseline, 1~6 weeks ]
    Number of participants with abnormal Ventricular rate, PR interval, QRS interval, and QT interval

  6. Number of participants with abnormalities in Physical examination [ Time Frame: SAD, FE: Baseline, 1~2 weeks; MAD: Baseline, 1~6 weeks ]
    Number of participants with abnormal Physical examination results, including general appearance, skin, eyes, ears, nose, throat, head and neck (including thyroid), heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal, neurological system, and other body systems

  7. Pharmacokinetics (PK) of PS1 [ Time Frame: Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) ]
    AUC_Area under the serum concentration-time profile

  8. Pharmacokinetics (PK) of PS1 [ Time Frame: Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) ]
    Cmax_The peak post-dose concentration

  9. Pharmacokinetics (PK) of PS1 [ Time Frame: Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) ]
    Tmax_Time at which Cmax is observed

  10. Pharmacokinetics (PK) of PS1 [ Time Frame: Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) ]
    T1/2_Terminal phase elimination half-life

  11. Pharmacokinetics (PK) of PS1 [ Time Frame: Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) ]
    MRT_Mean Residence Time

  12. Pharmacokinetics (PK) of PS1 [ Time Frame: Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) ]
    CL/F_Apparent Clearance

  13. Pharmacokinetics (PK) of PS1 [ Time Frame: Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) ]
    Volume of distribution

  14. Pharmacokinetics (PK) of PS1 [ Time Frame: Day 1 and 2 (SAD, FE and MAD portion), Day 28 and 29 (MAD portion only) ]
    Rac_Accumulation ratio

  15. Potential efficacy (For Cohort 7 and 8 only) [ Time Frame: MAD: Baseline, 1~6 weeks ]
    Changes from baseline of fasting plasma glucose (FPG) at each post-treatment visit; Changes from baseline of C-peptide at each post-treatment visit; Changes from baseline of hemoglobin A1c (HbA1c) at Visit 10 and Visit 11.

  16. Exploratory Endpoints (For MAD only) [ Time Frame: MAD: Baseline, 1~6 weeks ]
    Changes from baseline of serum PDIA4



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

For all cohorts, a subject is eligible for the study if all of the following apply:

  1. Both genders aged 18 to 80 years, inclusive at screening
  2. Body mass index (BMI) between 18.5 and 40.0 kg/m2
  3. Negative test for hepatitis B surface antigen (HBsAg), Anti-HCV antibody, and human immunodeficiency virus (HIV) at screening
  4. Is willing to follow the trial life style instruction and protocol procedure
  5. Able to understand and sign the informed consent form.

    Inclusion criteria applied for healthy subjects (Cohorts 1~6)

  6. Overtly healthy subject, who is considered to be generally healthy based on medical history, vital signs, laboratory tests, 12-lead EKG, and physical examination, as judged by the investigator
  7. With HbA1c value of < 6.5% and fasting plasma glucose < 110 mg/dL at Screening
  8. With estimated glomerular filtration rate (eGFR) > 80 ml/min

    Inclusion criteria applied for T2DM patients (Cohort 7 and 8)

  9. Diagnosis of T2DM
  10. T2DM treated with diet and exercise alone currently, for at least 2 weeks prior to Screening
  11. With HbA1c level between 6.5% to 9.0% and fasting plasma glucose level between 130 mg/dL to 250 mg/dL at Screening
  12. With estimated glomerular filtration rate (eGFR) > 60 ml/min
  13. For patients taking medication for other chronic disease, the medication should be on a stable dose for at least 4 weeks prior to Screening, and should not be a strong CYP enzyme inhibitor or inducer

Exclusion Criteria:

For all cohorts, a subject meeting any of the following exclusion criteria will be excluded from study participation.

  1. History of Type I diabetes mellitus
  2. Under the systemic treatment of any prescription medication or over-the-counter (OTC) medication that may interfere with the safety or PK assessment judged by the investigator within 7 days before Screening
  3. Received strong CYP enzyme inhibitor or inducer within 14 days before Screening
  4. Received any vaccination within 14 days before Screening
  5. Has required insulin therapy within the past 12 weeks
  6. Known hypersensitivity to any of the components of PS1 tablet
  7. History of major clinically significant hematological, renal, respiratory, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, musculoskeletal, immune, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing) within 3 months of Screening that may significantly alter the biomarker panel, require receiving any systemic medications, or interfere with the interpretation of data, as judged by the investigator
  8. History of pancreatitis
  9. Serum amylase > 1.5 × Upper Limit of Normal (ULN) or lipase > 1.5 × ULN
  10. Clinically significant ECG abnormality at Screening
  11. History of cancer (malignancy) or have ever received any anti-cancer therapy
  12. Regular smoker Regular smoker is defined as who smokes every day (≥ 1 cigarette/day in average in the past 8 weeks of Screening)
  13. Consumed greater than 3 units of alcoholic beverages per day in average for the past 4 weeks before Screening One unit is equivalent to one can of beer (20% alcohol; about 45 mL)
  14. Received any investigational therapy from another clinical study or underwent any major surgeries within the last 12 weeks prior to Screening.
  15. Took glucose-lowering medications within the last 2 weeks prior to Screening
  16. Received any systemic steroids (inhaled and intranasal steroids are permitted) or other immunosuppressive medications within 4 weeks prior to Screening
  17. Have ever received cell therapy or organ transplantation
  18. Other conditions not suitable for participating in this study as judged by the investigator
  19. Any conditions that forbid the completion of study procedures due to the local regulatory restrictions
  20. Female subject of childbearing potential who:

    • Is lactating; or
    • Has a positive pregnancy test result at Screening; or
    • Refuses to adopt at least one form of birth control (refer to Section 5.3) from signing informed consent to the end of the study.
  21. Male subject with a female spouse/partner who is of childbearing potential refuses to adopt at least one form of birth control (refer to Section 5.3) from signing informed consent to the end of the study.

    Exclusion criteria applied for healthy subjects (Cohorts 1~6):

  22. History of type II diabetes mellitus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05176210


Contacts
Layout table for location contacts
Contact: Yuyu Chung, Master +886-2-2793-8665 ext 1595 pm@pharmasaga.com

Locations
Layout table for location information
Taiwan
Mingche Liu Recruiting
Taipei, Taiwan
Contact: Mingche Liu, M.D. Ph.D         
Principal Investigator: Mingche Liu, M.D. Ph.D         
Sponsors and Collaborators
Pharmasaga Co. Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Mingche Liu, MD., PhD Taipei Medical University Hospital
Layout table for additonal information
Responsible Party: Pharmasaga Co. Ltd.
ClinicalTrials.gov Identifier: NCT05176210    
Other Study ID Numbers: PS1-01
First Posted: January 4, 2022    Key Record Dates
Last Update Posted: April 15, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases